Analyst Price Target is $7.50
▲ +1,596.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Panbela Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 1,596.07% upside from the last price of $0.44.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Panbela Therapeutics. This Buy consensus rating has held steady for over two years.
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm's product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.